Monday, March 7, 2022

UPL

UPL

02.08.2022 - CLSA on UPL Maintain Buy CMP 736.95 Target 1000
10.05.2022 - CLSA on UPL Maintain Buy CMP 777 Target 1000
25.03.2022 - CLSA on UPL Maintain Buy CMP 796.10 Target 1100
03.03.2022 - MS on UPL Maintain Overweight CMP 689 Target 951
01.02.2022 - Jefferies on UPL Maintain Buy CMP 776 Target 1005
01.02.2022 - CLSA on UPL Maintain Buy CMP 776 Target 1100
06.01.2022 - CLSA On UPL Maintain Buy CMP 764 Target 1100
06.01.2022 - CLSA On UPL Maintain Buy Target 1100
16.12.2021 - Antique on UPL - Maintain Buy - Target Rs.960

Jefferies on UPL (AR Analysis)  : 30.08.2021

*Buy, TP Rs 965
*UPL envisages to grow margin-accretive Differentiated Solutions from 29% of sales now to 50% by FY26 
*Innovation rate could rise to 30% over 3-5 yrs (21% now)
*ESG focus continues & Synergies on track

CLSA ON UPL : 03.08.2021

• Maintain BUY, Target unchanged at Rs 1000/share
* Good quarter despite cost pressures
• Differentiated products/solutions to drive next leg of growth
* Strong volume growth was a clear positive surprise across key markets

KOTAK INSTL EQ ON UPL : 03.08.2021

* Kotak Insti Eq has a Sell rating on UPL as it doesn't see any major surprises to FY22 earnings
* Q1 Adj EBITDA Came in 5% Under Estimates
* High Commodity Prices Should Support Price Hikes
* Don't See Any Major Surprises To FY22 Earnings
* Lack Of Near-term Catalysts Deny Multiples Room For Re-rating
* MAINTAIN SELL TARGET: 760

JPMORGAN ON UPL : 03.08.2021

* JPMorgan maintains Overweight rating on UPL, says strong commodity pricing should support valuation
* MAINTAIN OVERWEIGHT TARGET: 880
* Favourable Agri Environment To Support Momentum With Upcoming LatAm Season In Focus
• Sustainable Agriculture & Bio-solution Are Long-term Positives
* Strong Commodity Pricing Should Support Valuation

CLSA ON UPL : 03.08.2021

* CLSA Maintains Buy call on UPL as it believes co has posted healthy earnings in Q1 despite cost pressures
* Good Quarter Despite Cost Pressures
* Strong Volume Growth A Clear Positive Surprise Across Key Markets
* Retained Its FY22 Guidance
* Continued Focus On Differentiated Products Remains A Long-term Growth Driver
* MAINTAIN BUY TARGET: 1,000

ERIS

ERIS(Eris Lifesciences Ltd) 18.01.2023 -  Macquarie  on  ERIS Maintain Outperform CMP 625.75 Target 830